Full-Time

Associate Director Brand Marketing

Brand Marketing, Haematology

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

Barcelona, Spain + 4 more

More locations: Haywards Heath, UK | Esplugues de Llobregat, Barcelona, Spain | Hattersheim am Main, Germany | Munich, Germany

Hybrid

Flexible and hybrid working models are offered.

Bachelor's

Category
Growth & Marketing (1)
Required Skills
Branding/Brand Strategy
CRM

Get referred to CSL

See people who can refer or advise you

Requirements
  • A graduate degree or equivalent is required.
  • Eight to ten years of healthcare experience, including at least seven years in pharmaceutical or biotech brand sales and marketing.
  • A proven track record of driving brand strategy with operational excellence and delivering above-market results.
  • Experience leading above-country marketing initiatives and influencing diverse, multicultural matrix teams.
  • Strong analytical skills and the ability to translate insights into actionable strategies and tactics.
  • Proficiency in customer relationship management systems and data-driven marketing tools.
  • Excellent project management skills with experience leading complex, multi-stakeholder initiatives.
  • Excellent spoken and written English.
Responsibilities
  • Drive the development of brand and disease-area strategies for the International region, aligned with corporate and portfolio goals.
  • Act as the primary marketing partner for affiliates and foster a collaborative international marketing community.
  • Develop integrated, insight-driven brand strategies tailored to diverse markets.
  • Map and prioritize archetypes and ensure targeted positioning and messaging.
  • Identify short- and long-term opportunities, challenges, and lifecycle-management initiatives.
  • Lead market analysis to inform strategic decisions and optimize plans.
  • Build aligned, customer-focused brand plans and ensure disciplined regional implementation.
  • Define key performance indicators and monitor performance, adjusting activities based on data and insights.
  • Lead the 3M Brand Team and ensure clear agendas, actions, and follow-through.
  • Serve as the central contact for internal and external stakeholders across Marketing, Medical, Regulatory, Finance, and key opinion leader and healthcare professional networks.
  • Manage the regional brand budget to maximize return on investment.
Desired Qualifications
  • A postgraduate qualification is preferred.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Germany approved HEMGENIX reimbursement on 2 April 2025, unlocking broader European commercialization.
  • CSL completed Austria and Denmark HEMGENIX launches in 2025, expanding revenue conversion.
  • CSL's November 2025 VarmX option targets a 2029 launch in urgent anticoagulant reversal.

What critics are saying

  • CSL cut up to 3,000 jobs in August 2025, signaling persistent margin stress.
  • The Pentagon ended mandatory flu shots in April 2026, pressuring Seqirus demand.
  • A failed VarmX Phase 3 program would waste CSL's US$117 million upfront and delay 2029 growth.

What makes CSL unique

  • CSL dominates plasma-derived therapies, built on global donor collection and manufacturing scale.
  • HEMGENIX proved durable four-year efficacy, strengthening CSL's premium hemophilia franchise.
  • CSL still owns rare-disease and vaccines expertise across Behring, Seqirus, and Vifor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

StockTitan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.